{"result": {"id": "bc825b7c-c409-417e-8a45-6661b145d3a8", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>FUROSEMIDE<|>PERSON<|>Furosemide is a loop diuretic with varying half-life depending on patient condition (30-60min in normal patients, 75-155min in anuric patients, 11-20h in severe hepatic/renal impairment)\")\n##\n(\"entity\"<|>CALCIUM CHANNEL BLOCKERS<|>ORGANIZATION<|>Class of antihypertensive drugs abbreviated as CCB in the text\")\n##\n(\"entity\"<|>ANGIOTENSIN RECEPTOR BLOCKERS<|>ORGANIZATION<|>Class of antihypertensive drugs abbreviated as ARB in the text\")\n##\n(\"entity\"<|>ANGIOTENSIN CONVERTING ENZYME INHIBITORS<|>ORGANIZATION<|>Class of antihypertensive drugs abbreviated as ACEI in the text\")\n##\n(\"entity\"<|>NATIONAL MEDICAL PRODUCTS ADMINISTRATION<|>ORGANIZATION<|>Chinese regulatory body for drugs (mentioned as reference for drug usage guidelines)\")\n##\n(\"entity\"<|>U.S. FOOD AND DRUG ADMINISTRATION<|>ORGANIZATION<|>U.S. regulatory body referenced for drug half-life information\")\n##\n(\"relationship\"<|>FUROSEMIDE<|>CALCIUM CHANNEL BLOCKERS<|>Both are classes of antihypertensive medications mentioned in the same document<|>3)\n##\n(\"relationship\"<|>ANGIOTENSIN RECEPTOR BLOCKERS<|>ANGIOTENSIN CONVERTING ENZYME INHIBITORS<|>Both are classes of antihypertensive medications mentioned in the same document<|>4)\n##\n(\"relationship\"<|>NATIONAL MEDICAL PRODUCTS ADMINISTRATION<|>U.S. FOOD AND DRUG ADMINISTRATION<|>Both are drug regulatory agencies referenced in the document<|>3)\n##\n(\"relationship\"<|>ALISKIREN<|>CALCIUM CHANNEL BLOCKERS<|>Both are antihypertensive agents mentioned in the document<|>3)\n##\n(\"relationship\"<|>RESERPINE<|>ANGIOTENSIN CONVERTING ENZYME INHIBITORS<|>Both are antihypertensive agents mentioned in the document<|>3)\n##\n(\"relationship\"<|>CLONIDINE<|>ANGIOTENSIN RECEPTOR BLOCKERS<|>Both are antihypertensive agents mentioned in the document<|>3)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558654, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 554, "prompt_tokens": 3534, "total_tokens": 4088, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3008}, "prompt_cache_hit_tokens": 3008, "prompt_cache_miss_tokens": 526}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: �钾增高\n直接肾素抑制剂\t\t\t\t腹泻、高血钾\n阿利吉仑\t40(34~41)\t150~300\t1\t\n中枢作用药物\t\t\t\t\n利血平\t45~168\t0. 125~0. 5\t1~2\t鼻充血 ,心动过缓 ,消化性溃疡\n可乐定\t12(6~24)\t0. 1~0. 8\t2~3\t低血压 , 口干 ,嗜睡\n可乐定贴片\t12. 7(6~23)\t0. 25\t1/周\t皮肤过敏\n甲基多巴\t2\t250~1000\t2~3\t肝功能损害 ,免疫失调\n直接血管扩张药\n米诺地尔\t2. 8~4. 2\t\t5~100              \t1\t多毛症\n肼屈嗪\t3~7\t\t25~100              \t2\t狼疮综合征\n注 :CCB为钙通道阻滞药;ARB为血管紧张素受体阻滞药;ACEI为血管紧张素转换酶抑制药。\n* 呋塞米的消除半衰期正常人为 30~60min,无尿患者延长至 75~155min,肝肾功能同时严重受损者延长至 11~20h。\n1. 药物的使用方法、不良反应、适应证和禁忌证 ,详见国家药品监督管理局批准的有关药物的说明书。\n2. 半衰期主要参考各药物说明书以及美国食品药品监督管理局网站 ,但各药物说明书对于半衰期的描述并不完全一致 ,仅供参考。\n　　3. 控释和缓释剂型药物的药代动力学和药效学特性与普通药物差异较大 ,大多不提供半衰期数值或提供的是药物成分的半衰期 。临床用药应 关注此类药物的药效时长而不是药物成分的半衰期。\n\n表 16   常用单片复方制剂\n\n主要组分与每片剂量\t每天服药片数\t每天服药次数\t主要不良反应\n氯沙坦钾/氢氯噻嗪\n氯沙坦钾 50mg/氢氯噻嗪 12. 5 mg   氯沙坦钾 100mg/氢氯噻嗪 12. 5 mg 氯沙坦钾 100mg/氢氯噻嗪 25mg\t\n1~2 1 1\t\n1\n1\n1\t偶见血管神经性水肿 ,血钾异常\n缬沙坦/氢氯噻嗪\t\t\t偶见血管神经性水肿 ,血钾异常\n缬沙坦 80mg/氢氯噻嗪 12. 5 mg\t1~2\t1\t\n厄贝沙坦/氢氯噻嗪\n厄贝沙坦 150mg/氢氯噻嗪 12. 5 mg\t\n1\t\n1\t偶见血管神经性水肿 ,血钾异常\n替米沙坦/氢氯噻嗪\t\t\t偶见血管神经性水肿 ,血钾异常\n替米沙坦 40mg/氢氯噻嗪 12. 5 mg\t1\t1\t\n替米沙坦 80mg/氢氯噻嗪 12. 5 mg\t1\t1\t\n奥美沙坦/氢氯噻嗪\n奥美沙坦 20mg/氢氯噻嗪 12. 5 mg\t\n1~2\t\n1\t偶见血管神经性水肿 ,血钾异常\n坎地沙坦酯/氢氯噻嗪\t\t\t偶见血管神经性水肿 ,血钾异常\n�\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>ALISKIREN<|>PERSON<|>Aliskiren is a direct renin inhibitor used for treating hypertension with a dosage range of 150-300 mg and a half-life of 40 hours\")\n##\n(\"entity\"<|>RESERPINE<|>PERSON<|>Reserpine is a centrally acting drug used for hypertension with a dosage range of 0.125-0.5 mg and a half-life of 45-168 hours\")\n##\n(\"entity\"<|>CLONIDINE<|>PERSON<|>Clonidine is a centrally acting drug used for hypertension with a dosage range of 0.1-0.8 mg and a half-life of 12 hours\")\n##\n(\"entity\"<|>CLONIDINE PATCH<|>PERSON<|>Clonidine patch is a transdermal form of clonidine with a dosage of 0.25 mg and a half-life of 12.7 hours\")\n##\n(\"entity\"<|>METHYLDOPA<|>PERSON<|>Methyldopa is a centrally acting drug used for hypertension with a dosage range of 250-1000 mg and a half-life of 2 hours\")\n##\n(\"entity\"<|>MINOXIDIL<|>PERSON<|>Minoxidil is a direct vasodilator used for hypertension with a dosage range of 5-100 mg and a half-life of 2.8-4.2 hours\")\n##\n(\"entity\"<|>HYDRALAZINE<|>PERSON<|>Hydralazine is a direct vasodilator used for hypertension with a dosage range of 25-100 mg and a half-life of 3-7 hours\")\n##\n(\"entity\"<|>LOSARTAN POTASSIUM/HYDROCHLOROTHIAZIDE<|>ORGANIZATION<|>A combination drug used for hypertension containing losartan potassium and hydrochlorothiazide\")\n##\n(\"entity\"<|>VALSARTAN/HYDROCHLOROTHIAZIDE<|>ORGANIZATION<|>A combination drug used for hypertension containing valsartan and hydrochlorothiazide\")\n##\n(\"entity\"<|>IRBESARTAN/HYDROCHLOROTHIAZIDE<|>ORGANIZATION<|>A combination drug used for hypertension containing irbesartan and hydrochlorothiazide\")\n##\n(\"entity\"<|>TELMISARTAN/HYDROCHLOROTHIAZIDE<|>ORGANIZATION<|>A combination drug used for hypertension containing telmisartan and hydrochlorothiazide\")\n##\n(\"entity\"<|>OLMESARTAN/HYDROCHLOROTHIAZIDE<|>ORGANIZATION<|>A combination drug used for hypertension containing olmesartan and hydrochlorothiazide\")\n##\n(\"entity\"<|>CANDESARTAN CILEXETIL/HYDROCHLOROTHIAZIDE<|>ORGANIZATION<|>A combination drug used for hypertension containing candesartan cilexetil and hydrochlorothiazide\")\n##\n(\"relationship\"<|>ALISKIREN<|>RESERPINE<|>Both are drugs used for treating hypertension<|>3)\n##\n(\"relationship\"<|>CLONIDINE<|>CLONIDINE PATCH<|>Both are forms of clonidine used for treating hypertension<|>8)\n##\n(\"relationship\"<|>MINOXIDIL<|>HYDRALAZINE<|>Both are direct vasodilators used for treating hypertension<|>5)\n##\n(\"relationship\"<|>LOSARTAN POTASSIUM/HYDROCHLOROTHIAZIDE<|>VALSARTAN/HYDROCHLOROTHIAZIDE<|>Both are combination drugs used for treating hypertension<|>4)\n##\n(\"relationship\"<|>IRBESARTAN/HYDROCHLOROTHIAZIDE<|>TELMISARTAN/HYDROCHLOROTHIAZIDE<|>Both are combination drugs used for treating hypertension<|>4)\n##\n(\"relationship\"<|>OLMESARTAN/HYDROCHLOROTHIAZIDE<|>CANDESARTAN CILEXETIL/HYDROCHLOROTHIAZIDE<|>Both are combination drugs used for treating hypertension<|>4)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_29a31f0e14823f6bb3ec0f2c99d9d6fa850f9ffb2c3366bb430eaa8d64fe1b13_v2"}